LPCUF (Lee's Pharmaceutical Holdings) LT-Debt-to-Total-Asset : 0.03 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lee's Pharmaceutical Holdings's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.03.

Lee's Pharmaceutical Holdings's long-term debt to total assets ratio increased from Jun. 2023 (0.03) to Jun. 2024 (0.03). It may suggest that Lee's Pharmaceutical Holdings is progressively becoming more dependent on debt to grow their business.

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Chart

Lee's Pharmaceutical Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

Lee's Pharmaceutical Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Calculation

Lee's Pharmaceutical Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	9.548	/	370.133
	=	0.03

Lee's Pharmaceutical Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	10.05	/	326.34
	=	0.03

Lee's Pharmaceutical Holdings (OTCPK:LPCUF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (OTCPK:LPCUF) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

00950:Hong Kong

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines